Exhibit 10.1
SEPARATION AGREEMENT
THIS SEPARATION AGREEMENT (the “Agreement”) is made and entered into on August 15, 2025 by and between Adaptimmune, LLC (“Adaptimmune”) and Cintia Piccina (“Piccina”) and is effective as of the Effective Date as defined in Section 9 below.
WHEREAS, Piccina and Adaptimmune previously entered into an Employment Agreement, dated as of February 26, 2024 (the “Employment Agreement”).
WHEREAS, Piccina’s employment with Adaptimmune has ended, and Adaptimmune and Piccina wish to conclude their employment relationship on mutually satisfactory terms and to settle fully and finally all matters and potential disputes that Piccina may have with Adaptimmune and certain others.
NOW, THEREFORE, in consideration of the mutual promises contained herein and intending to be legally bound, Adaptimmune and Piccina hereby agree as follows:
The Payment will be made in lump-sum form in the next available Company month-end pay date following the Effective Date of this Agreement assuming that Piccina has not validly revoked the Agreement. Piccina acknowledges and agrees that the Payment is in full satisfaction of Adaptimmune’s obligations to Piccina under the Executive Severance Policy dated March 10, 2017, as amended (the “Severance Policy”). Piccina will be entitled to any accrued and unused vacation time, as communicated separately, regardless of whether Piccina elects to sign this Agreement.
Piccina’s share options will continue to vest, subject to the rules of the Adaptimmune Therapeutics plc Employee 2016 Share Option Scheme and related plan documents (collectively, the “Plan”) and in accordance with the respective vesting schedules, until the Separation Date. Subject to the Plan rules, and any applicable legal or regulatory requirements: (i) the exercise period for vested market value options held by Piccina over 1,125,648 ordinary shares will expire on January 30, 2032; and (ii) Piccina will be permitted a period of 12 months from the Separation Date to exercise any other market value share options that have vested as of the Separation Date. All unvested share options as of the Separation Date will lapse and be forfeited as of the Separation Date. The further terms of Piccina’s share options are governed by the Plan rules. Piccina understands and agrees that she will not receive any payment or other compensation from Adaptimmune in respect of her share options and shares.
BY SIGNING THIS AGREEMENT, EMPLOYEE ACKNOWLEDGES DOING SO VOLUNTARILY AFTER CAREFULLY READING AND FULLY UNDERSTANDING EACH PROVISION AND ALL OF THE EFFECTS OF THIS AGREEMENT, WHICH INCLUDES A RELEASE OF KNOWN AND UNKNOWN CLAIMS AND A RESTRICTION ON FUTURE LEGAL ACTION AGAINST ADAPTIMMUNE AND OTHER RELEASED PARTIES.
IN WITNESS WHEREOF, and intending to be legally bound hereby, the parties execute this Separation Agreement. | |
Employee: By: /s/ Cintia Piccina Printed Name: Cintia Piccina Date: August 15, 2025 | For Adaptimmune, LLC: By: /s/ Adrian Rawcliffe Printed Name: Adrian Rawcliffe Title: CEO Date: August 15, 2025 |